Gastroenterology and Hepatology

Host: Samuel J. Klempner, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers. Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.

Host: Yelena Janjigian, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers. Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.

Host: Yelena Janjigian, MD Host: Samuel J. Klempner, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers. Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.

Host: Yelena Janjigian, MD Host: Samuel J. Klempner, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers. Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.

Host: Cem Akin, MD, PhD Guest: Daniel J. DeAngelo, MD, PhD Guest: Matthew J. Hamilton, MD Patients with indolent systemic mastocytosis frequently report a symptom burden disproportionate to measurable disease burden. Anti-mediator intervention is not always successful in improving the quality of life of these patients. But the treatment landscape is changing. Join Drs. Cem Akin, Daniel DeAngelo, and Matthew Hamilton offer key clinical insights into this changing standard of care for ISM and discuss why allergists, hematologists, and gastroenterologists are at the vanguard of this change.

Host: Cem Akin, MD, PhD Guest: Daniel J. DeAngelo, MD, PhD New tyrosine kinase inhibitor (TKI) treatment options can significantly reduce symptom burden in patients with moderate to severe indolent systemic mastocytosis (ISM). Studies report that systemic mastocytosis and ISM are often undiagnosed for years. Improve your diagnosis and treatment of ISM by tapping into the expertise of a multidisciplinary team, including allergists, gastroenterologists, and hematologists, and increase your awareness of diagnostic criteria, the varied presentations of ISM, and new treatment options that move beyond traditional anti-mediator therapy.

Host: Tauseef Ali, MD, FACG, AGAF Host: Sabina Ali, MD Host: Neil Nandi, MD, FACP Host: Tina Aswani-Omprakash, MPH A South Asian pediatric gastroenterologist discusses the epidemiology of IBD, distinct phenotypes, the latest clinical data from the mainland and diaspora, patient burden, and the importance of providing culturally competent care.

Host: Arun B. Jesudian, MD Host: Robert Rahimi, MD, MSCR Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population. Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

Host: Robert Rahimi, MD, MSCR Host: Arun B. Jesudian, MD Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population. Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

Host: Patricia P. Bloom, MD Host: Robert Rahimi, MD, MSCR Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population. Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

Host: Patricia P. Bloom, MD Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population. Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

Host: Patricia P. Bloom, MD Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population. Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

Host: Robert Rahimi, MD, MSCR Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population. Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

Host: Arun B. Jesudian, MD Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population. Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

Host: Arun B. Jesudian, MD Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and mood or personality changes, as liver disease progresses, the symptoms of HE tend to worsen and can lead to coma and death if left untreated. This curriculum aims to improve the referral process from the initial onset of HE to consultation with a hepatologist by increasing knowledge of available tools for the identification, diagnosis, and treatment of HE. Ultimately, this educational program is intended to help narrow the gap in care for the underserved HE population. Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Andrew Keaveny, MD Guest: Don Rockey, MD Extrahepatic manifestations of decompensated cirrhosis confer significant additional risks for mortality, and a multidisciplinary team of healthcare professionals is involved in the care of these patients. This program will discuss two critical aspects of advanced liver disease: variceal bleeding and hepatorenal syndrome (HRS). These complications pose significant challenges in the management of patients with cirrhosis. Clinically-significant portal hypertension, identified by a hepatic venous pressure gradient >10mmHg, predicts the development of variceal hemorrhage, hepatic encephalopathy, ascites, and HRS, all hallmarks of decompensation and multi-organ failure. Faculty will discuss a common patient presentation to highlight best practices in evidence-based care of patients with variceal bleeding and HRS/acute kidney injury.

Host: Yelena Janjigian, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers. Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.

Host: Samuel J. Klempner, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers. Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.

Host: Yelena Janjigian, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers. Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.

Host: Yelena Janjigian, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers. Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.